Role of type I interferon in inducing a protective immune response: Perspectives for clinical applications

Cytokine and Growth Factor Reviews

Volumn 26, Issue 2, 2015, Pages 195-201

  Rizza, Paola ^a   Moretti, Franca ^a   Capone, Imerio ^a   Belardelli, Filippo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cancer immunotherapy; Dendritic cell; Immunity; Interferon; Vaccine adjuvant

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; CANCER VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERFERON; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; PROTEIN P53; SURVIVIN; SYT SSX FUSION VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DEATH; CELL DIFFERENTIATION; CELL INTERACTION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; HUMAN; IMMUNITY; IMMUNOGENICITY; INNATE IMMUNITY; INTERFERON PRODUCTION; KIDNEY CARCINOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; SHORT SURVEY; SIGNAL TRANSDUCTION; SYNOVIAL SARCOMA; TUMOR IMMUNITY; ADAPTIVE IMMUNITY; ANIMAL; BIOSYNTHESIS; IMMUNOLOGY; MOUSE; NEOPLASMS;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; INTERFERON-ALPHA; MICE; NEOPLASMS; VIRAL VACCINES;

EID: 84926476403     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.10.002     Document Type: Short Survey

References (58)

1. Vilcek J. Fifty years of interferon research: aiming at a moving target. Immunity 2006, 25:343-348.
2. Gresser I. The antitumor effects of interferon: a personal history. Biochimie 2007, 89:723-728.
3. Belardelli F., Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 1996, 17:369-372.
4. Belardelli F., Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 2002, 23:201-208.
5. Rizza P., Capone I., Moretti F., Proietti E., Belardelli F. IFN-alpha as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical use. Expert Rev Vaccines 2011, 10:487-498.
6. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14:461-470.
7. Santini S.M., Lapenta C., Logozzi M., Parlato S., Spada M., Di Pucchio T., et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000, 191:1777-1788.
8. Affabris E., Jemma C., Rossi G.B. Isolation of interferon-resistant variants of Friend erythroleukemia cells: effects of interferon and ouabain. Virology 1982, 120:441-452.
9. Gresser I., Carnaud C., Maury C., Sala A., Eid P., Woodrow D., et al. Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon alpha/beta treatment in mice. J Exp Med 1991, 173:1193-1203.
10. Ferrantini M., Belardelli F. Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Sem Cancer Biol 2000, 10:145-157.
11. Ferrantini M., Proietti E., Santodonato L., Gabriele L., Peretti M., Plavec I., et al. Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res 1993, 53:1107-1112.
12. + T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. J Immunol 1994, 153:4604-4615.
13. + T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice. Cancer Res 1998, 58:5795-5802.
14. Gogas H., Ioannovich J., Dafni U., Stavropoulou-Giokas C., Frangia K., Tsoutsos D., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006, 354:709-718.
15. Proietti E., Bracci L., Puzelli S., Di Pucchio T., Sestili P., De Vincenzi E., et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 2002, 169:375-383.
16. Tough D.F. Modulation of T-cell function by type I interferon. Immunol Cell Biol 2012, 90:492-497.
17. Lorenzi S., Mattei F., Sistigu A., Bracci L., Spadaro F., Sanchez M., et al. Type I IFNs control antigen retention and survival of CD8alpha(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J Immunol 2011, 186:5142-5150.
18. Diamond M.S., Kinder M., Matsushita H., Mashayekhi M., Dunn G.P., Archambault J.M., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011, 208:1989-2003.
19. Fuertes M.B., Woo S.R., Burnett B., Fu Y.X., Gajewski T.F. Type I interferon response and innate immune sensing of cancer. Trends Immunol 2013, 34:67-73.
20. Merad M., Sathe P., Helft J., Miller J., Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 2013, 31:563-604.
21. Bracci L., Capone I., Moschella F., Proietti E., Belardelli F. Exploiting dendritic cells in the development of cancer vaccines. Expert Rev Vaccines 2013, 12:1195-1210.
22. Parlato S., Santini S.M., Lapenta C., Di Pucchio T., Logozzi M., Spada M., et al. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 2001, 98:3022-3029.
23. + T cell response. J Immunol 2003, 170:5195-5202.
24. Lapenta C., Santini S.M., Logozzi M., Spada M., Andreotti M., Di Pucchio T., et al. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med 2003, 198:361-367.
25. Lapenta C., Santini S.M., Spada M., Donati S., Urbani F., Accapezzato D., et al. IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur J Immunol 2006, 36:2046-2060.
26. Parlato S., Romagnoli G., Spadaro F., Canini I., Sirabella P., Borghi P., et al. LOX-1 as a natural IFN-alpha-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. Blood 2010, 115:1554-1563.
27. Santini S.M., Lapenta C., Donati S., Spadaro F., Belardelli F., Ferrantini M. Interferon-alpha-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12. PLoS ONE 2011, 6:e17364.
28. Bracci L., Schumacher R., Provenzano M., Adamina M., Rosenthal R., Groeper C., et al. Efficient stimulation of T cell responses by human IFN-alpha-induced dendritic cells does not require Toll-like receptor triggering. J Immunother 2008, 31:466-474.
29. Spadaro F., Lapenta C., Donati S., Abalsamo L., Barnaba V., Belardelli F., et al. IFN-alpha enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 2012, 119:1407-1417.
30. Vermi W., Fisogni S., Salogni L., Scharer L., Kutzner H., Sozzani S., et al. Spontaneous regression of highly immunogenic Molluscum contagiosum virus (MCV)-induced skin lesions is associated with plasmacytoid dendritic cells and IFN-DC infiltration. J Investig Dermatol 2011, 131:426-434.
31. Farkas A., Tonel G., Nestle F.O. Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells. Br J Dermatol 2008, 158:921-929.
32. Di Pucchio T., Pilla L., Capone I., Ferrantini M., Montefiore E., Urbani F., et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 2006, 66:4943-4951.
33. Hawkins R.E., Macdermott C., Shablak A., Hamer C., Thistlethwaite F., Drury N.L., et al. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J Immunother 2009, 32:424-429.
34. Amato R.J., Shingler W., Goonewardena M., de Belin J., Naylor S., Jac J., et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother 2009, 32:765-772.
35. Trepiakas R., Berntsen A., Hadrup S.R., Bjorn J., Geertsen P.F., Straten P.T., et al. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy 2010, 12:721-734.
36. Alfaro C., Perez-Gracia J.L., Suarez N., Rodriguez J., Fernandez de Sanmamed M., Sangro B., et al. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J Immunol 2011, 187:6130-6142.
37. Kameshima H., Tsuruma T., Torigoe T., Takahashi A., Hirohashi Y., Tamura Y., et al. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci 2011, 102:1181-1187.
38. Kawaguchi S., Tsukahara T., Ida K., Kimura S., Murase M., Kano M., et al. SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group. Cancer Sci 2012, 103:1625-1630.
39. Kameshima H., Tsuruma T., Kutomi G., Shima H., Iwayama Y., Kimura Y., et al. Immunotherapeutic benefit of alpha-interferon (IFNalpha) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci 2013, 104:124-129.
40. Tanaka T., Kitamura H., Inoue R., Nishida S., Takahashi-Takaya A., Kawami S., et al. Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer - results from phase I clinical trials. Clin Dev Immunol 2013, 2013:262967.
41. Zeestraten E.C., Speetjens F.M., Welters M.J., Saadatmand S., Stynenbosch L.F., Jongen R., et al. Addition of interferon-alpha to the p53-SLP(R) vaccine results in increased production of interferon-gamma in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int J Cancer 2013, 132:1581-1591.
42. Rizza P., Capone I., Urbani F., Montefiore E., Rapicetta M., Chionne P., et al. Evaluation of the effects of human leukocyte IFN-alpha on the immune response to the HBV vaccine in healthy unvaccinated individuals. Vaccine 2008, 26:1038-1049.
43. Launay O., Grabar S., Bloch F., Desaint C., Jegou D., Lallemand C., et al. Effect of sublingual administration of interferon-alpha on the immune response to influenza vaccination in institutionalized elderly individuals. Vaccine 2008, 26:4073-4079.
44. Couch R.B., Atmar R.L., Cate T.R., Quarles J.M., Keitel W.A., Arden N.H., et al. Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine 2009, 27:5344-5348.
45. Miquilena-Colina M.E., Lozano-Rodriguez T., Garcia-Pozo L., Saez A., Rizza P., Capone I., et al. Recombinant interferon-alpha2b improves immune response to hepatitis B vaccination in haemodialysis patients: results of a randomised clinical trial. Vaccine 2009, 27:5654-5660.
46. Nistico P., Capone I., Palermo B., Del Bello D., Ferraresi V., Moschella F., et al. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer 2009, 124:130-139.
47. Sun S., Zhang X., Tough D.F., Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 1998, 188:2335-2342.
48. Dunn G.P., Bruce A.T., Sheehan K.C., Shankaran V., Uppaluri R., Bui J.D., et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005, 6:722-729.
49. Kotredes K.P., Gamero A.M. Interferons as inducers of apoptosis in malignant cells. J Interferon Cytokine Res: Off J Int Soc Interferon Cytokine Res 2013, 33:162-170.
50. Duewell P., Steger A., Lohr H., Bourhis H., Hoelz H., Kirchleitner S.V., et al. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8 T cells. Cell Death Differ 2014, [Epub ahead of print]. 10.1038/cdd.2014.96.
51. Kroemer G., Galluzzi L., Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013, 31:51-72.
52. Fang T.C., Schaefer U., Mecklenbrauker I., Stienen A., Dewell S., Chen M.S., et al. Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. J Exp Med 2012, 209:661-669.
53. Genin P., Lin R., Hiscott J., Civas A. Recruitment of histone deacetylase 3 to the interferon-A gene promoters attenuates interferon expression. PLoS ONE 2012, 7:e38336.
54. Hudak L., Tezeeh P., Wedel S., Makarevic J., Juengel E., Tsaur I., et al. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion. Prostate 2012, 72:1719-1735.
55. Sugimoto K., Shimada M., Utsunomiya T., Morine Y., Imura S., Ikemoto T., et al. Valproic acid enhances the anti-tumor effect of pegylated interferon-alpha towards pancreatic cancer cell lines. Anticancer Res 2014, 34:3403-3409.
56. Mokyr M.B., Place A.T., Artwohl J.E., Valli V.E. Importance of signaling via the IFN-alpha/beta receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother 2006, 55:459-468.
57. Burnette B.C., Liang H., Lee Y., Chlewicki L., Khodarev N.N., Weichselbaum R.R., et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res 2011, 71:2488-2496.
58. Sistigu A., Yamazaki T., Vacchelli E., Chaba K., Enot D.P., Adam J., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014, [Epub ahead of print]. 10.1038/nm.3708.